Medicinal Materials Research Center
The Medicinal Materials Research Center develops novel pharmaceutical materials for the treatment of incurable diseases. Our research interests are i) development of cancer immunotherapeutics, ii) development of tumor immune microenvironment reprogramming technology, and iii) development of precision cancer immunotherapy technology. Simultaneously, we strive to realize precision medicine (prevention, diagnosis, and treatment) for the treatment of incurable diseases through the development of patient-specific treatment technology based on ‘theragnosis’ technology and immune fusion technology.
Sun Hwa Kim
Head, Medicinal Materials Research Center
- Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity (Biomaterials, 2021)
- The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis (Biomaterials, 2021)
- Visible-Light-Triggered Prodrug Nanoparticles Combine Chemotherapy and Photodynamic Therapy to Potentiate Checkpoint Blockade Cancer Immunotherapy (ACS Nano, 2021)
- Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance (Journal of Controlled Release, 2021)
- Systemic delivery of CRISPR/Cas9 to hepatic tumors for cancer treatment using altered tropism of lentiviral vector (Biomaterials, 2021)
- A novel therapeutic modality using CRISPR-engineered dendritic cells to treat allergies (Biomaterials, 2021)
- A Trojan-Horse Strategy by In Situ Piggybacking onto Endogenous Albumin for Tumor-Specific Neutralization of Oncogenic MicroRNA (ACS Nano, 2021)
- In vivo tracking of bioorthogonally labeled T-cells for predicting therapeutic efficacy of adoptive T-cell therapy (Journal of Controlled Release, 2021)
- Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity (Science Advances, 2020)
Tumor microenvironment and immune cell reprogramming
- Anticancer immune response activation based on tumor microenvironment remodelling
- Immune cell activation and reprogramming technology
- Immune checkpoint regulation technology
- Tumor-targeted cell therapy
Development of anti-cancer vaccine platform and immunotherapeutics
- Development of cancer vaccine nanoplatforms
- Development of cancer vaccine delivery technology
- Discovering novel immunotherapeutics and immune modulators
Development of complex formulation of immunotherapeutics and precision anticancer immunotherapy technology
- Development of complex formulation of immunotherapeutics
- Development of combination cancer immunotherapy technology
